IONS - IONIS PHARMACEUTICALS INC

QQQ $ 441.90 $ 4.10 (0.94 %)

DIA $ 391.28 $ 4.23 (1.09 %)

SPY $ 524.64 $ 5.12 (0.99 %)

TLT $ 96.94 $ -1.10 (-1.12 %)

GLD $ 220.67 $ -0.78 (-0.35 %)

Previous Close

$ 47

Open

$ 47.42

Bid

$ 44.34 x 208

Ask

$ 49.66 x 215

Day's Range

$ 46.65 - $ 47.42

52 Week Range

$ 35.95 - $ 54.44

Volume

1,280,762

Average Volume

Market Cap

6.86B

Beta (5Y Monthly)

$ 0.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-21-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-09-2023	06-30-2023	10-Q
6	05-03-2023	03-31-2023	10-Q
7	02-22-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	11-03-2021	09-30-2021	10-Q
13	08-04-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	02-24-2021	12-31-2020	10-K
16	11-04-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	03-02-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-01-2019	12-31-2018	10-K
24	11-06-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-07-2018	03-31-2018	10-Q
27	02-28-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	03-01-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q
35	02-26-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-05-2015	06-30-2015	10-Q
38	05-05-2015	03-31-2015	10-Q
39	03-02-2015	12-31-2014	10-K
40	11-07-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Guggenheim Maintains Buy on Ionis Pharmace...
08/02/2024 19:27:39

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target...

Goldman Sachs Maintains Sell on Ionis Phar...
08/02/2024 16:37:12

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell and raises the price target ...

Barclays Maintains Equal-Weight on Ionis P...
08/02/2024 15:04:07

Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target fro...

12 Analysts Have This To Say About Ionis P...
08/02/2024 12:00:30

Needham Reiterates Buy on Ionis Pharmaceut...
08/02/2024 10:15:43

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

BMO Capital Downgrades Ionis Pharmaceutica...
08/02/2024 09:15:41

BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lo...

Ionis Pharmaceuticals Q2 2024 Adj. EPS $(0...
08/01/2024 11:37:34

Alcyone Therapeutics Announces Continued E...
07/31/2024 13:08:46

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therape...

Leerink Partners Upgrades Ionis Pharmaceut...
07/24/2024 10:47:12

Leerink Partners analyst Mani Foroohar upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and ra...

TD Cowen Maintains Buy on Ionis Pharmaceut...
07/23/2024 17:04:00

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $54 ...

B of A Securities Maintains Buy on Ionis P...
07/23/2024 13:39:22

B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price targe...

Needham Reiterates Buy on Ionis Pharmaceut...
07/22/2024 18:35:10

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

ionis-rare-development-disorder-drug-candidate-could-be-differentiated-from-peer-ultragenyx-analyst

Ionis' Rare Development Disorder Drug Cand...
07/22/2024 17:04:26

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinic...

Ionis Pharmaceuticals Announces Phase 1/2 ...
07/22/2024 11:02:22

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive results from the completed multiple ascending dose (MAD) po...

Ionis Pharmaceuticals Has Completed Enroll...
07/18/2024 11:06:39

The Latest Analyst Ratings For Ionis Pharm...
07/16/2024 19:00:35

B of A Securities Maintains Buy on Ionis P...
07/16/2024 17:41:17

B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price targe...

Jefferies Upgrades Ionis Pharmaceuticals t...
07/16/2024 12:53:13

Jefferies analyst Akash Tewari upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Buy and raises the price ta...

Assessing Ionis Pharmaceuticals: Insights ...
06/27/2024 13:00:28

Stifel Maintains Hold on Ionis Pharmaceuti...
06/27/2024 12:20:17

Stifel analyst Paul Matteis maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Hold and raises the price target from $50 t...